Modulation by lipid mediators of immune complex-induced lung inflammation in mice.
The present study characterized a murine model of immune complex-induced pneumonitis and investigated the role of platelet-activating factor (PAF) and eicosanoids as mediators of lung neutrophil infiltration and hemorrhagic lesions. Rabbit antibodies to bovine serum albumin were injected into the airways and bovine serum albumin was injected intravenously into C3H/HePas and BALB/c mice. After 24 h, a significant increase in neutrophil infiltration and hemoglobin concentration in the bronchoalveolar lavage fluid and lung parenchyma was observed in both strains despite the C3H/HePas strain being 10 times more sensitive to PAF. Neutrophil influx and vascular lesions were not affected by pre-treatment of the mice with the PAF receptor antagonist, WEB 2170 (5-(2-chlorphenyl)carbonyl)-3,4-dihydro- 10-methyl-3-((4-morpholinyl)-2H,7H-cyclopenta(4,5)thieno(3,2-f)(1,2,4)-t riazolo-(4,3-a)(1,4)-diazepine). In contrast, neutrophil influx and vascular lesions were increased by the cyclo-oxygenase inhibitor, indomethacin, and reduced by the inhibitor of leukotriene synthesis, MK 886 (3-[1-(4-chlorobenzyl-3-t-butyl-thio-t-isopropyl-indol-2y-1]-2-2-+ ++dimethylpropanoic acid) and by the leukotriene B4 receptor antagonist, RO 0254094 (2-[(5-carboxypentyl)-6-[6-[3,4-dihidro-4-oxo-8-propyl-2H-1-benzop yran-7-yl)hexyl] benzenepropanoic acid). Increased levels of leukotriene B4, leukotriene C4/D4, thromboxane B2 were found in bronchoalveolar lavage fluid 4 h after induction of the reaction. There is also a tendency to increased prostaglandins E2 levels. Neutrophil infiltration and vascular lesions in immune complex-induced pneumonitis in mice are mediated by leukotriene B4.
Steil
A A
AA
University of Vale do Itajaí, Santa Catarina, Brazil.
Tavares de Lima
W
W
Jancar
S
S
D000818:Animals; D000936:Antigen-Antibody Complex / Q000276:immunology*; D001183:Arthus Reaction / Q000276:immunology; D001381:Azepines / Q000494:pharmacology; D001578:Benzopyrans / Q000494:pharmacology; D001808:Blood Vessels / Q000187:drug effects / Q000502:physiology; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry / Q000166:cytology; D002199:Capillary Permeability / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D015777:Eicosanoids / Q000378:metabolism; D006454:Hemoglobins / Q000187:drug effects / Q000378:metabolism; D007105:Immune Complex Diseases / Q000276:immunology*; D007211:Indoles / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D008168:Lung / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D009504:Neutrophils / Q000187:drug effects / Q000473:pathology; D009195:Peroxidase / Q000187:drug effects / Q000378:metabolism; D010972:Platelet Activating Factor / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D011014:Pneumonia / Q000276:immunology; D018102:Receptors, Leukotriene B4 / Q000037:antagonists & inhibitors; D013045:Species Specificity; D014230:Triazoles / Q000494:pharmacology; D002722:Chlorobenzenes
D000936:Antigen-Antibody Complex; D001381:Azepines; D001578:Benzopyrans; D015777:Eicosanoids; D006454:Hemoglobins; D007211:Indoles; D007213:Indomethacin; D016859:Lipoxygenase Inhibitors; D009195:Peroxidase; D010972:Platelet Activating Factor; D010975:Platelet Aggregation Inhibitors; D018102:Receptors, Leukotriene B4; D014230:Triazoles; C117414:Ro 0254094; C060893:MK-886; D002722:Chlorobenzenes; C063964:bepafant